Kidney failure

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

Retrieved on: 
Thursday, March 21, 2024
Research, Other Health, General Health, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Pelvic floor dysfunction, MGH, Kidney disease, Gene, Organization, Survival, Massachusetts General Hospital, Transplant, Inflammation, Immunosuppression, Kidney failure, Mortality, Coagulation, Hope, Doctor of Philosophy, Expanded access, Quality of life, Genome, Transgene, Hospital, Kidney, Dialysis, CD40L, Courage, Kidney transplantation, Medicine, Dentistry

eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
  • Following the procedure, the patient is in good condition and recovering well at MGH.
  • Yet the demand for organs far outpaces supply, with more than 90,000 individuals on the kidney waitlist and approximately 25,000 kidney transplants performed each year.
  • Decades of progress in cross-species transplantation, accelerated by the advancement of modern genome editing tools and next-generation sequencing, have enabled eGenesis to progress genetically engineered organs to the clinical setting.

Kidney Patients Raise National Health Alert on Phosphorus

Retrieved on: 
Thursday, April 4, 2024
Hyperphosphatemia, Transplant, Nutrient, Hyperkalemia, Congress, Patient, Stroke, Social media, Investment, United States Senate, Phosphorus, Representative, Ways and means committee, Research, Education, Itch, Risk, ESRD, Policy, FMLA, CMS, Senate, Food, Federation, Kidney failure, Prospective payment system, Death, House, Executive (government), Louisiana House of Representatives, Graduate diploma, Dialysis, FDA, Government, Seizure, CKD, Mortality, Kidney disease, Medicare, Physician, Pharmaceutical industry

WASHINGTON, April 4, 2024 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient consumer organization in the U.S., is raising public awareness on April 5, National Phosphorus Awareness Day, about the devastating impacts of unmanaged phosphorus levels in individuals with advanced chronic kidney disease (CKD).

Key Points: 
  • Kidney patients are at an increased risk for high phosphorus (termed hyperphosphatemia) due to their decreased kidney function and an inability to excrete excess nutrients, including phosphorus.
  • Kidney patients are medically complex and typically manage multiple co-related health conditions including hyperphosphatemia , hyperkalemia , CKD associated pruritis (CKD-aP) , and more .
  • Kidney patients and all people of goodwill involved in the fight to improve kidney health are making their voices heard by contacting their U.S.
  • Since 1969, The American Association of Kidney Patients has been a patient-led organization driving policy discussions on kidney patient care choice and medical innovation.

BLACK AMERICANS AT HIGHER RISK FOR KIDNEY FAILURE AS BLACK HEALTH MATTERS, NATIONAL KIDNEY FOUNDATION FIGHT FOR EQUITY DURING NATIONAL KIDNEY MONTH

Retrieved on: 
Thursday, March 14, 2024
Health, BHM, NKF, Risk, Diabetes, Global health, Patient, National Kidney Foundation, EQUITY, ALL, Social media, Kidney failure, Kidney disease, Kidney, Chronic kidney disease, World Kidney Day, All, Pharmaceutical industry

NEW YORK, March 14, 2024 /PRNewswire/ -- Black Health Matters (BHM)– a leading nonprofit health advocacy organization that provides health and wellness information that is rooted in medical expertise to the Black community – is partnering with the National Kidney Foundation (NKF) to spread awareness about kidney equity during National Kidney Month. Observed in March each year, National Kidney Month aims to raise awareness about kidney health and chronic kidney disease. The month also includes World Kidney Day – a global health awareness day focusing on the importance of kidneys and the impact of kidney disease - which is observed March 14.

Key Points: 
  • Observed in March each year, National Kidney Month aims to raise awareness about kidney health and chronic kidney disease.
  • The month also includes World Kidney Day – a global health awareness day focusing on the importance of kidneys and the impact of kidney disease - which is observed March 14.
  • NKF continues to fight to get Kidney Equity for All - a commitment to make a difference in ALL kidney patients' lives!
  • "As an organization that spotlights health disparities and the importance of health in the Black community, kidney health has become a silent epidemic in our community," said Roslyn Young-Daniels, President, and Founder of Black Health Matters.

Kidney Foundation Marks 60th Anniversary

Retrieved on: 
Thursday, February 29, 2024
Diabetes, Incidence, Cancer, Investment, Quality of life, Dialysis, Kidney disease, Smoke, Hope, Volunteering, Stroke, Risk, World Kidney Day, Transplant, Smoking, Patient, Survival, Kidney, Research, Kidney failure, Pharmaceutical industry

Learn more during Kidney Health Month in March

Key Points: 
  • Montreal, Quebec--(Newsfile Corp. - February 29, 2024) - When the Kidney Foundation of Canada was launched in 1964, a person with kidney failure had very little hope of survival.
  • As we work to raise awareness of these vital organs, The Kidney Foundation is reflecting on the significant progress made in the past six decades to improve the quality of life and health outcomes of kidney patients.
  • "These advances are providing new hope for people diagnosed with kidney disease and those living with kidney failure."
  • The Kidney Foundation is ramping up advocacy efforts to ensure that every Canadian has access to the care they need to prevent or delay the progression of kidney disease.

Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease

Retrieved on: 
Thursday, February 29, 2024
AstraZeneca, Caregiver, American Kidney Fund, Eli Lilly and Company, AKF, Dialysis, Pfizer, Notifiable disease, Nephrology, Boehringer Ingelheim, Patient, Genetic testing, Kidney disease, Senior counsel, Disease, Kidney, Diagnosis, Research, Kidney failure, Pharmaceutical industry

During Kidney Month, AKF calls on members of the kidney community and the general public to join in solidarity in support of everyone affected by kidney disease.

Key Points: 
  • During Kidney Month, AKF calls on members of the kidney community and the general public to join in solidarity in support of everyone affected by kidney disease.
  • One of the hallmarks of Kidney Month at AKF is Kidney Action Week , which will be held March 18-22.
  • This free, virtual event will bring together patients, nephrologists, renal dieticians, caregivers and other kidney experts for a weeklong series of sessions about a variety of topics related to kidney disease, including dialysis, kidney disease prevention, kidney-friendly eating, transplant, innovations in kidney disease and more.
  • In addition, people with kidney disease have a higher chance of developing other health problems, such as heart disease.

Simple HealthKit Launches Expanded Kidney Health Evaluation for Patients with Diabetes (KED) Program to Help Payers Improve Patient Health, Boost STAR Ratings & Meet HEDIS Measures

Retrieved on: 
Monday, February 26, 2024
Chronic kidney disease, HEDIS, Social, Dialysis, Simple, KED, DIY, Government, STAR, Conference, University, Risk, CKD, Medicare, ViVe, Patient, Health (Apple), Kidney, Kidney failure

At the heart of the program is Simple HealthKit’s new Expanded Kidney Health Test, which evaluates kidney function and kidney damage, and is available via in-clinic or at-home settings.

Key Points: 
  • At the heart of the program is Simple HealthKit’s new Expanded Kidney Health Test, which evaluates kidney function and kidney damage, and is available via in-clinic or at-home settings.
  • Diabetes is the leading cause of chronic kidney disease (CKD)—about 1 in 3 adults with diabetes have CKD.
  • At-home kidney health tests could drastically reduce Medicare expenditures associated with CKD, while boosting Star Ratings, and satisfying KED HEDIS® measures for MY2024.
  • Simple HealthKit already works with multiple payers across the U.S. including government agencies, universities and private healthcare plans like Imperial Health.

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

Retrieved on: 
Friday, February 23, 2024
Head, SAN, European Commission, EMA, Marketing, Irbesartan, MAA, European, Food, CSL, Risk, Civil service commission, Therapy, CHMP, CSL Vifor, Patient, Immunoglobulin A, Kidney disease, Kidney, CMA, Proteinuria, Kidney failure, Pharmaceutical industry

SAN DIEGO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of sparsentan for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion >1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). IgAN is a rare kidney disease and a leading cause of kidney failure. The CHMP opinion provides the basis for the European Commission’s final decision regarding CMA for sparsentan. If approved in Europe, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for the treatment of IgAN.

Key Points: 
  • The CHMP opinion provides the basis for the European Commission’s final decision regarding CMA for sparsentan.
  • If approved in Europe, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for the treatment of IgAN.
  • In August 2022, Travere Therapeutics and CSL Vifor announced they had submitted a Marketing Authorization Application (MAA) for CMA to the EMA.
  • In 2021, Travere Therapeutics granted CSL Vifor exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand.

Where You Live Impacts Your Ability to Save a Life Through Living Organ Donation, According to the 2024 American Kidney Fund Report Card

Retrieved on: 
Thursday, February 22, 2024
Ambassador, Chronic kidney disease, Health insurance, American Kidney Fund, Latino, AKF, Dialysis, News, Report card, Transplant, Skin, Life, HIPP, CKD, Disability, House, FMLA, Telephone numbers in Hungary, Policy, Family, Legislation, Louisiana House of Representatives, Patient, Kidney disease, Insurance, Kidney, Representative, Child, Health equity, The Report Card, Mortality, Research, Senate, Kidney failure

Receiving a kidney from a living donor is the best option for someone in need of a new kidney.

Key Points: 
  • Receiving a kidney from a living donor is the best option for someone in need of a new kidney.
  • However, six states – Alabama, Montana, New Hampshire, Tennessee, South Dakota and Vermont – have zero policy protections (F grade) for living organ donors.
  • How All 50 States + DC Fared on the 2024 State of the States: American Kidney Fund Report Card
    Currently, chronic kidney disease (CKD) affects more than 1 in 7 adults in the U.S.
  • “Where you live should not impact whether you are able to save a life through kidney donation, but our 2024 Report Card suggests that this may be the case.

OneLegacy Inspires Hollywood to Host Community Wellness Event Featuring Celebrity Guests and Hip Hop Legend, Freeway to Close Black History Month and Kickoff National Kidney Month

Retrieved on: 
Tuesday, February 27, 2024
Surgery, Entertainment, Events, Concerts, Other Health, African American, Celebrity, Music, General Health, Consumer, Health, BHL, Black History Month, African Americans, Diabetes, HBCU, Marketing, Internet, Connect the dots, Eye, Radio, Risk, Pelvic floor dysfunction, Kidney failure, Transplant, Death, RSVP, Ecosystem, Yoga, Family, SLIC, Heart, Civilization, Advocate, Hip hop music, FREE, Social media, OTT

The star-studded community event will feature Hip Hop legend and kidney transplant recipient, Leslie Pridgen, as well as celebrity TV and radio host, Nicole Richardson, better known as Nikki Rich and writer, comedian, and filmmaker, J.

Key Points: 
  • The star-studded community event will feature Hip Hop legend and kidney transplant recipient, Leslie Pridgen, as well as celebrity TV and radio host, Nicole Richardson, better known as Nikki Rich and writer, comedian, and filmmaker, J.
  • Sports, Lifestyle in Culture (SLiC) is an official partner of the event.
  • The media brand under the SLiC umbrella, Black Hollywood Live, will cover the event, amplifying the culture and narrative of the impactful initiative on all available social and streaming platforms.
  • Nicole Richardson of the Nikki Rich Show, a TV/radio host and Oprah Winfrey Network Ambassador, recently received a lifesaving kidney transplant.

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Retrieved on: 
Monday, February 26, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Week, UPCR, HKEX, CRR, Safety, Patient, Lupus nephritis, Clinical trial, CDE, IND, KZR, NMPA, Kidney failure, Pharmaceutical industry

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).

Key Points: 
  • Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).
  • Everest will join Kezar and enroll patients in China as part of the ongoing PALIZADE trial, a global, placebo-controlled Phase 2b clinical trial evaluating the efficacy and safety of two dose levels of zetomipzomib or placebo in patients with active LN.
  • In September 2023, Everest obtained exclusive rights to develop and commercialize zetomipzomib in Greater China, South Korea and Southeast Asia.
  • “With the approval of the zetomipzomib IND in China, Everest now has three medicines in the renal space either commercialized or in clinical development.